{"id":2710,"date":"2022-11-09T06:00:52","date_gmt":"2022-11-09T06:00:52","guid":{"rendered":"https:\/\/magazines.uthscsa.edu\/schools\/?p=2710"},"modified":"2023-07-18T15:51:54","modified_gmt":"2023-07-18T15:51:54","slug":"breaking-cancers-will-to-survive","status":"publish","type":"post","link":"https:\/\/magazines.uthscsa.edu\/schools\/2022\/11\/09\/breaking-cancers-will-to-survive\/","title":{"rendered":"Breaking cancer\u2019s will to survive"},"content":{"rendered":"

The challenge of being first<\/h2>\n

By Michael Seringer<\/em><\/h4>\n

The search for a novel compound on which to design a first-in-class cancer therapy is a long, arduous\u00a0process. Daohong Zhou evaluated hundreds of compounds synthesized by the team of Guangrong Zheng, PhD, a medicinal chemist who specializes in the design and synthesis of natural and synthetic compounds at the University of Florida. Zhou and his team were looking for a compound that degraded a cancer\u2019s survival signal, termed BCL-xL, without being toxic to blood platelets.<\/p>\n

\n

\"\"Daohong Zhou, MD<\/strong><\/h4>\n
Professor of Biochemistry and Structural Biology; Director of the Center for Innovative Drug Discovery; Associate Director of Drug Discovery for the Mays Cancer Center<\/em><\/h5>\n
Company:<\/strong> <\/span>Dialectic Therapeutics (private)<\/h6>\n
Compound:<\/span><\/strong> Novel, small molecule \u2014 DT2216 (patented)<\/h6>\n
Indication:<\/strong><\/span> Cancer, relapsed and refractory malignancies<\/h6>\n
Stage:<\/strong> <\/span>Completed FDA investigational new drug application studies; in Phase 1 clinical trials, Mays Cancer Center<\/h6>\n
Timing:<\/strong> <\/span>Approximately five years<\/h6>\n
Funding:<\/strong><\/span> Approximately $24 million<\/h6>\n
\n
Taking a first-in-class compound from the lab to the clinic in an academic setting requires a competitive mindset.<\/em><\/span><\/h6>\n<\/blockquote>\n
\n

\u201cWe were the first to creatively use the proteolysis targeting chimera [PROTAC] technology to overcome the on-target and dose-limiting toxicity of BCL-xL inhibitors,\u201d Zhou said. \u201cWe are targeting cancer cells by converting the inhibitors into BCL-xL PROTACs that target BCL-xL to an E3 ligase minimally expressed in platelets but highly expressed in tumors.\u201d<\/p>\n

Zhou\u2019s goal of developing a first-in-class, cancer-fighting molecule was realized when DT2216 showed promise in vitro and in vivo in both human tumor xenograft models and patient-derived xenograft models. Zhou\u2019s team targeted cancer\u2019s will to survive with the launch of Dialectic Therapeutics and its first-in-class compound DT2216.<\/p>\n

The key to developing a compound with a unique mechanism of action and delivery starts with innovative ideas, cutting-edge technologies and solid medicinal chemistry and research.<\/p>\n

\u201cIt took a number of years of hard work as a team to advance DT2216 into the clinic,\u201d Zhou said.<\/p>\n

Zhou compares the development of a first-in-class drug to the process of making beautiful art. Both require absolute dedication, close attention to detail and constant assessment and iterative improvements.<\/p>\n

In addition, like artists who become popular in their lifetime, the research teams benefit from a little luck, Zhou said. By assembling a team of company founders composed of a medicinal chemist, physician scientist and biologist \u2014 and supported by Texas biotechnology experts and Dialectic Therapeutics investors and board members David Genecov, MD, and John Harkey \u2014 Zhou\u2019s team has helped create their own luck.<\/p>\n

Developing a first-in-class compound<\/strong><\/p>\n

The problem with developing a first-in-class drug is there is no previous research to guide the process.<\/p>\n

\u201cThere is no literature to refer to,\u201d Zhou said. \u201cThat\u2019s the challenge with developing a first-in-class drug; everything is new. Figuring out everything from the basic research to the proper dose regimen is difficult and time consuming when you have nothing to build on.\u201d<\/p>\n

Along with being a truly novel compound, DT2216 is too large to be absorbed from the GI tract and therefore requires intravenous therapy. Developing a lipid-based microemulsion to better deliver the drug to tumor cells provided additional intellectual property that enhanced the company\u2019s overall product portfolio.<\/p>\n

DT2216 is a first-generation compound built using a proprietary and novel antiapoptotic protein targeted degradation (APTaD\u2122) technology platform. Taking a first-in-class compound from the lab to the clinic in an academic setting requires a competitive mindset, according to Zhou. Both the Food and Drug Administration\u2019s investigational new drug application and human trials are an exhaustive process more aligned with the mindset prevalent in the pharmaceutical industry versus an academic institution, Zhou said.<\/p>\n

\n
\n
\"\"Innovative ideas need to be not only fostered by the right team, but also financed by partners with experience in biotechnology investing and drug discovery.<\/em><\/span><\/h6>\n<\/blockquote>\n

Competing against the pharmaceutical industry in drug development is very difficult; however, bringing a first-in-class molecule to the clinic gives startup biotech firms a slight advantage because they can change directions faster. They also maintain control over their molecule through animal and human trials. This is advantageous because they understand their compound better than anyone else and can catch small problems in the toxicity testing or clinical trials that might not be caught by another team not as familiar with the biochemistry and biology of the compound.<\/p>\n

Zhou believes much of the current success of Dialectic Therapeutics is the result of running a lean organization that invests everything back into research because it holds the vast majority of the equity.<\/p>\n

\u201cYou need a strong team with basic researchers to conduct cutting-edge research, clinicians who know patients\u2019 needs and how to translate basic research into the clinic, and a team who can help to advance leading compounds through the regulatory process into the clinic,\u201d Zhou said.<\/p>\n

Building the right focus and financing<\/strong><\/p>\n

Building an efficient drug development process requires team members to focus time and resources into research and development. The core value of scientific discovery comes at the expense of the usual biotech startup culture, which is focused on public perception, funding rounds and exit strategies. Getting a compound to the clinic is simply too difficult and expensive to focus on anything other than the drug. The motivating fact that many patients with incurable cancer are counting on a successfully designed drug increases the already high stakes.<\/p>\n

\u201cDrug discovery and development research is high risk and high reward,\u201d Zhou said. \u201cBecause the ultimate goal of our research is to improve health and quality of life and save lives, it is very satisfying to see that our hard work may eventually benefit patients.\u201d<\/p>\n

Innovative ideas need to be not only fostered by the right team, but also financed by partners with experience in biotechnology investing and drug discovery. Attracting the right private equity partners depends on a \u201cwell-validated therapeutic target with a large enough market to motivate investors,\u201d Zhou said. Too many researchers fail to assess market size and find out that there is little investor interest until it\u2019s too late, once too much time and money have been invested in the wrong target.<\/p>\n

\u201cFor investors to allocate resources to expensive preclinical and clinical studies, they have to see a large enough market for the compound,\u201d Zhou said.<\/p>\n

Just as important is selecting the right site on the target. For example, some PROTAC candidates never work because there is no adjacent lysine for the compound to act on. Then it is crucial that the compound be completely novel so that it can have strong intellectual property protection. It is almost impossible to attract investors to a compound that is already in the public domain, no matter how useful it is.<\/p>\n

Taking advantage of research grants is beneficial to startup drug discovery firms because this provides the necessary funding without dilution of ownership and loss of control of the startup company. Zhou and his team were awarded key grants from the National Institutes of Health and The Cancer Prevention and Research Institute of Texas to help fund development of DT2216. These grants create value beyond the dollars provided by validating the science and reducing risk for future investors, providing needed momentum for getting the compound through human trials.<\/p>\n

Zhou\u2019s success provides a blueprint for how other universities can enhance their own drug development programs. Universities can create external review of the commercial possibilities of novel targets and compounds, they can train faculty to spin off their own companies, and they can connect those companies with private equity.<\/p>\n","protected":false},"excerpt":{"rendered":"

The search for a novel compound on which to design a first-in-class cancer therapy is a long, arduous\u00a0process. Daohong Zhou evaluated hundreds of compounds synthesized by the team of Guangrong Zheng, PhD, a medicinal chemist who specializes in the design and synthesis of natural and synthetic compounds at the University of Florida. Zhou and his team were looking for a compound that degraded a cancer\u2019s survival signal, termed BCL-xL, without being toxic to blood platelets.<\/p>\n","protected":false},"author":598,"featured_media":2730,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[12],"magazine":[22],"issue-year":[48],"featured-story":[37],"class_list":["post-2710","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-research","magazine-future","issue-year-48","featured-story-landing-page"],"yoast_head":"\nBreaking cancer\u2019s will to survive - Magazines of the Schools at UT Health San Antonio<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/magazines.uthscsa.edu\/schools\/2022\/11\/09\/breaking-cancers-will-to-survive\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Breaking cancer\u2019s will to survive - Magazines of the Schools at UT Health San Antonio\" \/>\n<meta property=\"og:description\" content=\"The search for a novel compound on which to design a first-in-class cancer therapy is a long, arduous\u00a0process. Daohong Zhou evaluated hundreds of compounds synthesized by the team of Guangrong Zheng, PhD, a medicinal chemist who specializes in the design and synthesis of natural and synthetic compounds at the University of Florida. Zhou and his team were looking for a compound that degraded a cancer\u2019s survival signal, termed BCL-xL, without being toxic to blood platelets.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/magazines.uthscsa.edu\/schools\/2022\/11\/09\/breaking-cancers-will-to-survive\/\" \/>\n<meta property=\"og:site_name\" content=\"Magazines of the Schools at UT Health San Antonio\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-09T06:00:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-07-18T15:51:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/magazines.uthscsa.edu\/schools\/wp-content\/uploads\/sites\/11\/2022\/11\/113_1DF_13070105_114796665_6.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1440\" \/>\n\t<meta property=\"og:image:height\" content=\"960\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Karla Hignite\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Karla Hignite\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/magazines.uthscsa.edu\/schools\/2022\/11\/09\/breaking-cancers-will-to-survive\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/magazines.uthscsa.edu\/schools\/2022\/11\/09\/breaking-cancers-will-to-survive\/\"},\"author\":{\"name\":\"Karla Hignite\",\"@id\":\"https:\/\/magazines.uthscsa.edu\/schools\/#\/schema\/person\/6ce6ce71891598eb0173f0d285e7a66d\"},\"headline\":\"Breaking cancer\u2019s will to survive\",\"datePublished\":\"2022-11-09T06:00:52+00:00\",\"dateModified\":\"2023-07-18T15:51:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/magazines.uthscsa.edu\/schools\/2022\/11\/09\/breaking-cancers-will-to-survive\/\"},\"wordCount\":1244,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/magazines.uthscsa.edu\/schools\/2022\/11\/09\/breaking-cancers-will-to-survive\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/magazines.uthscsa.edu\/schools\/wp-content\/uploads\/sites\/11\/2022\/11\/113_1DF_13070105_114796665_6.jpg\",\"articleSection\":[\"Research\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/magazines.uthscsa.edu\/schools\/2022\/11\/09\/breaking-cancers-will-to-survive\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/magazines.uthscsa.edu\/schools\/2022\/11\/09\/breaking-cancers-will-to-survive\/\",\"url\":\"https:\/\/magazines.uthscsa.edu\/schools\/2022\/11\/09\/breaking-cancers-will-to-survive\/\",\"name\":\"Breaking cancer\u2019s will to survive - Magazines of the Schools at UT Health San Antonio\",\"isPartOf\":{\"@id\":\"https:\/\/magazines.uthscsa.edu\/schools\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/magazines.uthscsa.edu\/schools\/2022\/11\/09\/breaking-cancers-will-to-survive\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/magazines.uthscsa.edu\/schools\/2022\/11\/09\/breaking-cancers-will-to-survive\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/magazines.uthscsa.edu\/schools\/wp-content\/uploads\/sites\/11\/2022\/11\/113_1DF_13070105_114796665_6.jpg\",\"datePublished\":\"2022-11-09T06:00:52+00:00\",\"dateModified\":\"2023-07-18T15:51:54+00:00\",\"author\":{\"@id\":\"https:\/\/magazines.uthscsa.edu\/schools\/#\/schema\/person\/6ce6ce71891598eb0173f0d285e7a66d\"},\"breadcrumb\":{\"@id\":\"https:\/\/magazines.uthscsa.edu\/schools\/2022\/11\/09\/breaking-cancers-will-to-survive\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/magazines.uthscsa.edu\/schools\/2022\/11\/09\/breaking-cancers-will-to-survive\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/magazines.uthscsa.edu\/schools\/2022\/11\/09\/breaking-cancers-will-to-survive\/#primaryimage\",\"url\":\"https:\/\/magazines.uthscsa.edu\/schools\/wp-content\/uploads\/sites\/11\/2022\/11\/113_1DF_13070105_114796665_6.jpg\",\"contentUrl\":\"https:\/\/magazines.uthscsa.edu\/schools\/wp-content\/uploads\/sites\/11\/2022\/11\/113_1DF_13070105_114796665_6.jpg\",\"width\":1440,\"height\":960,\"caption\":\"Daohong Zhou, MD, with graduate student Jing Pei and research assistant professors Dongwen Lyu, PhD, MS (seated) and Sajid Khan, PhD.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/magazines.uthscsa.edu\/schools\/2022\/11\/09\/breaking-cancers-will-to-survive\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/magazines.uthscsa.edu\/schools\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Future\",\"item\":\"https:\/\/magazines.uthscsa.edu\/schools\/magazine\/future\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Breaking cancer\u2019s will to survive\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/magazines.uthscsa.edu\/schools\/#website\",\"url\":\"https:\/\/magazines.uthscsa.edu\/schools\/\",\"name\":\"Magazines of the Schools at UT Health San Antonio\",\"description\":\"Magazines of the Schools at UT Health San Antonio\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/magazines.uthscsa.edu\/schools\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/magazines.uthscsa.edu\/schools\/#\/schema\/person\/6ce6ce71891598eb0173f0d285e7a66d\",\"name\":\"Karla Hignite\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/1262fab3104fb7ec5678a5af8a40505f00dc05d47624676e2454cfe489013d98?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/1262fab3104fb7ec5678a5af8a40505f00dc05d47624676e2454cfe489013d98?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/1262fab3104fb7ec5678a5af8a40505f00dc05d47624676e2454cfe489013d98?s=96&d=mm&r=g\",\"caption\":\"Karla Hignite\"},\"url\":\"https:\/\/magazines.uthscsa.edu\/schools\/author\/hignite\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Breaking cancer\u2019s will to survive - Magazines of the Schools at UT Health San Antonio","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/magazines.uthscsa.edu\/schools\/2022\/11\/09\/breaking-cancers-will-to-survive\/","og_locale":"en_US","og_type":"article","og_title":"Breaking cancer\u2019s will to survive - Magazines of the Schools at UT Health San Antonio","og_description":"The search for a novel compound on which to design a first-in-class cancer therapy is a long, arduous\u00a0process. Daohong Zhou evaluated hundreds of compounds synthesized by the team of Guangrong Zheng, PhD, a medicinal chemist who specializes in the design and synthesis of natural and synthetic compounds at the University of Florida. Zhou and his team were looking for a compound that degraded a cancer\u2019s survival signal, termed BCL-xL, without being toxic to blood platelets.","og_url":"https:\/\/magazines.uthscsa.edu\/schools\/2022\/11\/09\/breaking-cancers-will-to-survive\/","og_site_name":"Magazines of the Schools at UT Health San Antonio","article_published_time":"2022-11-09T06:00:52+00:00","article_modified_time":"2023-07-18T15:51:54+00:00","og_image":[{"width":1440,"height":960,"url":"https:\/\/magazines.uthscsa.edu\/schools\/wp-content\/uploads\/sites\/11\/2022\/11\/113_1DF_13070105_114796665_6.jpg","type":"image\/jpeg"}],"author":"Karla Hignite","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Karla Hignite","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/magazines.uthscsa.edu\/schools\/2022\/11\/09\/breaking-cancers-will-to-survive\/#article","isPartOf":{"@id":"https:\/\/magazines.uthscsa.edu\/schools\/2022\/11\/09\/breaking-cancers-will-to-survive\/"},"author":{"name":"Karla Hignite","@id":"https:\/\/magazines.uthscsa.edu\/schools\/#\/schema\/person\/6ce6ce71891598eb0173f0d285e7a66d"},"headline":"Breaking cancer\u2019s will to survive","datePublished":"2022-11-09T06:00:52+00:00","dateModified":"2023-07-18T15:51:54+00:00","mainEntityOfPage":{"@id":"https:\/\/magazines.uthscsa.edu\/schools\/2022\/11\/09\/breaking-cancers-will-to-survive\/"},"wordCount":1244,"commentCount":0,"image":{"@id":"https:\/\/magazines.uthscsa.edu\/schools\/2022\/11\/09\/breaking-cancers-will-to-survive\/#primaryimage"},"thumbnailUrl":"https:\/\/magazines.uthscsa.edu\/schools\/wp-content\/uploads\/sites\/11\/2022\/11\/113_1DF_13070105_114796665_6.jpg","articleSection":["Research"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/magazines.uthscsa.edu\/schools\/2022\/11\/09\/breaking-cancers-will-to-survive\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/magazines.uthscsa.edu\/schools\/2022\/11\/09\/breaking-cancers-will-to-survive\/","url":"https:\/\/magazines.uthscsa.edu\/schools\/2022\/11\/09\/breaking-cancers-will-to-survive\/","name":"Breaking cancer\u2019s will to survive - Magazines of the Schools at UT Health San Antonio","isPartOf":{"@id":"https:\/\/magazines.uthscsa.edu\/schools\/#website"},"primaryImageOfPage":{"@id":"https:\/\/magazines.uthscsa.edu\/schools\/2022\/11\/09\/breaking-cancers-will-to-survive\/#primaryimage"},"image":{"@id":"https:\/\/magazines.uthscsa.edu\/schools\/2022\/11\/09\/breaking-cancers-will-to-survive\/#primaryimage"},"thumbnailUrl":"https:\/\/magazines.uthscsa.edu\/schools\/wp-content\/uploads\/sites\/11\/2022\/11\/113_1DF_13070105_114796665_6.jpg","datePublished":"2022-11-09T06:00:52+00:00","dateModified":"2023-07-18T15:51:54+00:00","author":{"@id":"https:\/\/magazines.uthscsa.edu\/schools\/#\/schema\/person\/6ce6ce71891598eb0173f0d285e7a66d"},"breadcrumb":{"@id":"https:\/\/magazines.uthscsa.edu\/schools\/2022\/11\/09\/breaking-cancers-will-to-survive\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/magazines.uthscsa.edu\/schools\/2022\/11\/09\/breaking-cancers-will-to-survive\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/magazines.uthscsa.edu\/schools\/2022\/11\/09\/breaking-cancers-will-to-survive\/#primaryimage","url":"https:\/\/magazines.uthscsa.edu\/schools\/wp-content\/uploads\/sites\/11\/2022\/11\/113_1DF_13070105_114796665_6.jpg","contentUrl":"https:\/\/magazines.uthscsa.edu\/schools\/wp-content\/uploads\/sites\/11\/2022\/11\/113_1DF_13070105_114796665_6.jpg","width":1440,"height":960,"caption":"Daohong Zhou, MD, with graduate student Jing Pei and research assistant professors Dongwen Lyu, PhD, MS (seated) and Sajid Khan, PhD."},{"@type":"BreadcrumbList","@id":"https:\/\/magazines.uthscsa.edu\/schools\/2022\/11\/09\/breaking-cancers-will-to-survive\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/magazines.uthscsa.edu\/schools\/"},{"@type":"ListItem","position":2,"name":"Future","item":"https:\/\/magazines.uthscsa.edu\/schools\/magazine\/future\/"},{"@type":"ListItem","position":3,"name":"Breaking cancer\u2019s will to survive"}]},{"@type":"WebSite","@id":"https:\/\/magazines.uthscsa.edu\/schools\/#website","url":"https:\/\/magazines.uthscsa.edu\/schools\/","name":"Magazines of the Schools at UT Health San Antonio","description":"Magazines of the Schools at UT Health San Antonio","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/magazines.uthscsa.edu\/schools\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/magazines.uthscsa.edu\/schools\/#\/schema\/person\/6ce6ce71891598eb0173f0d285e7a66d","name":"Karla Hignite","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/1262fab3104fb7ec5678a5af8a40505f00dc05d47624676e2454cfe489013d98?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/1262fab3104fb7ec5678a5af8a40505f00dc05d47624676e2454cfe489013d98?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1262fab3104fb7ec5678a5af8a40505f00dc05d47624676e2454cfe489013d98?s=96&d=mm&r=g","caption":"Karla Hignite"},"url":"https:\/\/magazines.uthscsa.edu\/schools\/author\/hignite\/"}]}},"_links":{"self":[{"href":"https:\/\/magazines.uthscsa.edu\/schools\/wp-json\/wp\/v2\/posts\/2710","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/magazines.uthscsa.edu\/schools\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/magazines.uthscsa.edu\/schools\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/magazines.uthscsa.edu\/schools\/wp-json\/wp\/v2\/users\/598"}],"replies":[{"embeddable":true,"href":"https:\/\/magazines.uthscsa.edu\/schools\/wp-json\/wp\/v2\/comments?post=2710"}],"version-history":[{"count":0,"href":"https:\/\/magazines.uthscsa.edu\/schools\/wp-json\/wp\/v2\/posts\/2710\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/magazines.uthscsa.edu\/schools\/wp-json\/wp\/v2\/media\/2730"}],"wp:attachment":[{"href":"https:\/\/magazines.uthscsa.edu\/schools\/wp-json\/wp\/v2\/media?parent=2710"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/magazines.uthscsa.edu\/schools\/wp-json\/wp\/v2\/categories?post=2710"},{"taxonomy":"magazine","embeddable":true,"href":"https:\/\/magazines.uthscsa.edu\/schools\/wp-json\/wp\/v2\/magazine?post=2710"},{"taxonomy":"issue-year","embeddable":true,"href":"https:\/\/magazines.uthscsa.edu\/schools\/wp-json\/wp\/v2\/issue-year?post=2710"},{"taxonomy":"featured-story","embeddable":true,"href":"https:\/\/magazines.uthscsa.edu\/schools\/wp-json\/wp\/v2\/featured-story?post=2710"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}